Lilly Expects Alimta Advisory Committee Review For Non-Small Cell Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is considering the pemetrexed sNDA for a July 27 Oncologic Drugs Advisory Committee meeting. First quarter sales of Alimta were $12 mil., including $7 mil. in initial stocking for the mesothelioma agent.